Pilot Study on Proteomics of Erythrocyte Proteins in Patients With COPD Based on TMT Technology

NCT05376618 | Completed DMC

• 1 other identifier: 2021-KY-060--01
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Chronic obstructive pulmonary disease (COPD), a common and complex disease characterized by persistent airflow limitation, is a leading cause of mortality worldwide. COPD and its comorbidity are associated with hypoxia condition. Further investigations on the cellular and molecular aspects of hypoxia in COPD should help to reveal the mechanisms underlying the development of this disease. Dysfunction of the erythrocyte, a main medium to transport oxygen through the blood, contributes to the prognosis and severity of COPD through hypoxia. It is proposed that dysregulated proteins in erythrocytes that impair oxygen transport may be involved in the development of COPD. However, a comprehensive study on altered proteins of erythrocytes in COPD is still lacking. Proteomics techniques and protein chip techniques provide a high throughput screening method to figure out characteristic inflammatory or metabolic markers of diseases. Therefore, this study is to evaluate the clinical significance of differential erythrocyte proteins in the course of COPD disease.

Conditions

Protein; Disease

Keywords

copd; erythrocyte; proteomics

Outcome Measures

Primary Outcomes (1)

• Protein biomarkers in erythrocyte predicting rapid decline of lung function

  The study is to identify the biomarkers and make sure which is associated with rapid decline of lung function. The study will include a total of 30 study subjects.

  2021-7-15 to 2022-7-15

Study Arms (2)

stable COPD

Other: no intervention

Healthy

Other: no intervention

Interventions

no intervention OTHER

no intervention

Healthy; stable COPD

Eligibility Criteria

• Age: 40 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The study will be an outpatient-based case-control study. 15 stable COPD patients and 15 healthy individuals will be recruited.

You may qualify if:

• Age from 40 to 80 years old; gender is not limited.
• Stable COPD
• Sign the informed consent with the willingness of obeying the protocol. -

You may not qualify if:

• Subjects with known other chronic respiratory diseases except for COPD (such as asthma, tuberculosis, bronchiectasis, interstitial lung disease, occupational lung diseases, sarcoidosis, lung cancer, et al);
• Subjects had been accepted lung lobectomy or transplantation;
• Subjects be ill with severe, or uncontrolled systemic diseases other than COPD (such as psychiatry diseases, chronic liver diseases, heart failure, auto-immunity diseases, chronic renal diseases, et al );
• Alcoholism, drug or solvents addition;
• Acute exacerbation COPD patients (AECOPD) -
• Age from 40 to 80 years old; gender is not limited.
• <!-- -->
• Subjects with known other chronic respiratory diseases (such as COPD, asthma, tuberculosis, bronchiectasis, interstitial lung disease, occupational lung diseases, sarcoidosis, lung cancer, et al);
• Subjects had been accepted lung lobectomy or transplantation;
• Subjects be ill with severe, or uncontrolled systemic diseases other than COPD (such as psychiatry diseases, chronic liver diseases, heart failure, auto-immunity diseases, chronic renal diseases, et al );
• Alcoholism, drug or solvents addition;

Sponsors & Collaborators

• Zhujiang Hospital: lead

Study Sites (1)

Zhujiang Hospital,Southern Medical Universtiy

Guangzhou, Guangdong, 510282, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

Peripheral blood

MeSH Terms

Conditions

Disease; Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms; Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 11, 2022
• First Posted: May 17, 2022
• Study Start: July 15, 2021
• Primary Completion: July 15, 2022
• Study Completion: July 15, 2022
• Last Updated: March 15, 2024

Record last verified: 2021-07

Locations

CN (1)